Reviewer's report
Title:Gynecomastia during imatinib mesylate treatment for gastrointestinal
tumor: a rare adverse event
Version: 1Date:9 July 2011
Reviewer: Vincenzo Pitini
Reviewer's report:
Dear Dr Timothy Shipley PhD,
In this paper Heli Liu et al. present six patients who developed gynecomastia
during treatment with imatinib.
Interestingly, three patients had increased serum estradiol levels which
suggested that the imbalance of sex hormone may be the cause of gynecomastia
during treatment with imatinib.
This paper has important implications for clinical management and given the
presented data the conclusions are right.
1. The question posed by the authors is well defined
2. The methods are appropriate and well described
3. The data are sound
4. The manuscript adhere to the relevant standards for reporting and data
deposition
5. The discussion and conclusions are well balanced and adequately supported
by the data
6. The title and abstract accurately convey what has been found
7. The writing is acceptable
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
Reviewer declares that he has no conflicts of interest.
With best wishes,
Prof. Vincenzo Pitini
Reviewer's report
Title:Gynecomastia during imatinib mesylate treatment for gastrointestinal
tumor: a rare adverse event
Version: 1Date:9 July 2011
Reviewer: Vincenzo Pitini
Reviewer's report:
Dear Dr Timothy Shipley PhD,
In this paper Heli Liu et al. present six patients who developed gynecomastia
during treatment with imatinib.
Interestingly, three patients had increased serum estradiol levels which
suggested that the imbalance of sex hormone may be the cause of gynecomastia
during treatment with imatinib.
This paper has important implications for clinical management and given the
presented data the conclusions are right.
1. The question posed by the authors is well defined
2. The methods are appropriate and well described
3. The data are sound
4. The manuscript adhere to the relevant standards for reporting and data
deposition
5. The discussion and conclusions are well balanced and adequately supported
by the data
6. The title and abstract accurately convey what has been found
7. The writing is acceptable
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
Reviewer declares that he has no conflicts of interest.
With best wishes,
Prof. Vincenzo Pitini
Please review this paper.
user
Reviewer's report
Title:Gynecomastia during imatinib mesylate treatment for gastrointestinal
tumor: a rare adverse event
Version: 1Date:9 July 2011
Reviewer: Vincenzo Pitini
Reviewer's report:
Dear Dr Timothy Shipley PhD,
In this paper Heli Liu et al. present six patients who developed gynecomastia
during treatment with imatinib.
Interestingly, three patients had increased serum estradiol levels which
suggested that the imbalance of sex hormone may be the cause of gynecomastia
during treatment with imatinib.
This paper has important implications for clinical management and given the
presented data the conclusions are right.
1. The question posed by the authors is well defined
2. The methods are appropriate and well described
3. The data are sound
4. The manuscript adhere to the relevant standards for reporting and data
deposition
5. The discussion and conclusions are well balanced and adequately supported
by the data
6. The title and abstract accurately convey what has been found
7. The writing is acceptable
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
Reviewer declares that he has no conflicts of interest.
With best wishes,
Prof. Vincenzo Pitini
assistant